DMK PHARMACEUTICALS Corp
DelistedCIK 887247fmd_0KF1FMS4HAGYY6M5ER8MEK4389Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Sep 30, 2023, 54 periods
| Line item | FY2014 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 6 | 13 | 15 | 22 | 3 | 2 | 5 |
| Cost of revenue | – | – | – | 5 | 7 | 10 | 15 | 6 | 7 | 6 |
| Gross profit | – | – | – | 2 | 6 | 5 | 7 | (4) | (5) | (1) |
| Research and development | – | 4 | 5 | 10 | 8 | 19 | 10 | 8 | 11 | 10 |
| Selling, general and administrative | – | 6 | 9 | 17 | 23 | 26 | 25 | 20 | 16 | 13 |
| Operating income | – | (10) | (14) | (25) | (25) | (39) | (29) | (36) | (32) | (25) |
| Interest expense | – | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 | – |
| Interest and investment income | – | – | – | 0 | 0 | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | – | (1) | 0 | 1 | (1) | 0 | (2) | 0 | (3) | (1) |
| Income before taxes | – | – | (14) | (24) | (26) | (39) | (28) | (36) | (35) | (26) |
| Income tax expense | – | – | – | (5) | (0) | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (8) | – | – | (19) | (26) | (39) | (28) | (36) | (35) | (26) |
| Net income | – | (11) | (14) | (19) | (26) | (39) | (28) | (49) | (46) | (26) |
| Net income to common shareholders | (8) | – | (14) | (21) | (26) | (39) | (28) | (49) | – | – |